Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 9/20 | 0.53 |
| ▸ | PARP1 | P09874 | 9/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20818213 | 0.91 | TRPC5 (0.51) | TRPC5PARP1TNK1TNKSTNKS2 | |
| SCHEMBL20831687 | 0.86 | TRPC5 (0.55) | TRPC5PARP1 | |
| SCHEMBL20831298 | 0.85 | TRPC5 (0.53) | TRPC5PARP1KDM4DTNKSTNKS2 | |
| SCHEMBL20818320 | 0.82 | TRPC5 (0.40) | TRPC5PARP1KDM4DTNKSTNKS2 | |
| SCHEMBL20818318 | 0.82 | TRPC5 (0.40) | TRPC5PARP1KDM4DTNKSTNKS2 | |
| SCHEMBL20831944 | 0.82 | TRPC5 (0.40) | TRPC5PARP1KDM4DTNKSTNKS2 | |
| SCHEMBL20831545 | 0.79 | TRPC5 (0.36) | TRPC5PARP1KDM4D | |
| SCHEMBL20831248 | 0.79 | TRPC5 (0.36) | TRPC5PARP1KDM4D | |
| SCHEMBL20831249 | 0.78 | TRPC5 (0.52) | TRPC5 | |
| SCHEMBL25699554 | 0.78 | TRPC5 (0.56) | TRPC5PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885PARP1 3298/4885KDM4D 2552/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | TRPC5 3626/4885PARP1 3410/4885KDM4D 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.